+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Quit Smoking Drugs Market Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • February 2025
  • Region: Global
  • The Business Research Company
  • ID: 5792701
The quit smoking drugs market size has grown rapidly in recent years. It will grow from $39.26 billion in 2024 to $44.62 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to health awareness campaigns, medical advancements, government initiatives, behavioral therapies integration, consumer attitude shifts.

The quit smoking drugs market size is expected to see rapid growth in the next few years. It will grow to $79.99 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to research and development investments, growing demand for cessation aids, targeted marketing and awareness campaigns, advancements in pharmacotherapy. Major trends in the forecast period include personalized treatment approaches, increasing health consciousness, digital therapeutics and apps, behavioral therapy integration, targeted marketing and education.

The increasing prevalence of smoking addiction is projected to drive the growth of the quit-smoking drug market in the future. Smoking involves inhaling and exhaling vapors from burning plant materials such as marijuana, hashish, tobacco, and others. Quit-smoking drugs are designed to reduce the urge to smoke by alleviating cravings for tobacco, and they are used as prescription medications to manage nicotine withdrawal symptoms, helping individuals quit smoking effectively. For example, in July 2022, Statistics Canada, a government agency based in Canada, reported a 5.8% increase in cigarette production compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3% from May 2022, reaching 1.4 billion in June 2022. Therefore, the growing prevalence of smoking addiction is driving the expansion of the quit-smoking drug market.

The growth of the quit-smoking drugs market is expected to be further accelerated by the rise of e-commerce. E-commerce, involving the online buying and selling of goods and services, provides a convenient platform for individuals seeking quit-smoking solutions. Quit-smoking drugs are increasingly accessible through online platforms, offering a discreet and user-friendly option for those aiming to quit smoking. For example, in August 2023, the U.S. Census Bureau estimated a 2.1% increase in U.S. retail e-commerce sales for the second quarter of 2023, reaching $277.6 billion. This surge in e-commerce activities contributes to the expansion of the quit-smoking drugs market.

A key trend in the quit-smoking drugs market is the focus on product innovation by major companies to strengthen their market positions. Notably, Swedish Match AB, a tobacco company based in Sweden, introduced ZYN Tobacco Gold in August 2022. ZYN Tobacco Gold is a nicotine pouch with a sweet tobacco flavor, offering a tobacco-free and smoke-free alternative. This innovative product addresses consumer preferences for reduced-risk alternatives, catering to those who wish to avoid tobacco consumption while still enjoying a nicotine kick in smoke-free environments.

Major companies in the quit smoking drugs market are concentrating on developing new formulations and delivery methods, such as generic tablets, to enhance their market leadership across various regions and gain a competitive advantage. Generic varenicline tablets are non-branded alternatives containing varenicline tartrate, which are bioequivalent to the original branded product and are utilized for smoking cessation therapy. For example, in January 2024, Lupin Limited, a pharmaceutical company based in India, launched new varenicline tablets in the United States, available in strengths of 0.5 mg and 1 mg. These tablets are generic versions of Chantix tablets (0.5 mg and 1 mg) produced by PF Prism C.V. and are designed to aid in smoking cessation treatment. As a partial agonist of the nicotinic acetylcholine receptor, varenicline stimulates the release of dopamine, helping to alleviate withdrawal symptoms and cravings associated with nicotine addiction. This dual mechanism reduces the pleasurable effects of smoking while providing some stimulation to minimize withdrawal symptoms.

In September 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, acquired the nicotine replacement therapy business from Haleon plc for $680 million (£500 million). The purpose of this acquisition is to strengthen Dr. Reddy's position in the global consumer healthcare market, particularly by enhancing its over-the-counter (OTC) offerings and expanding its presence in key international markets outside the United States. Haleon plc is a consumer health company based in the UK that specializes in drugs for nicotine addiction.

Major companies operating in the quit smoking drugs market include 22nd Century Group, Cipla Limited, Dr. Reddy's Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Novartis AG, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, Rusan Pharma Ltd., BioCorRx Inc., CV Sciences Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Gilla Inc., Hikma Pharmaceuticals PLC, Innovus Pharmaceuticals Inc., IntelGenx Technologies Corp.

North America was the largest region in the quit smoking drugs market in 2024. The regions covered in the quit smoking drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quit smoking drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Quit smoking drugs are specialized medications used by individuals aiming to quit smoking. These drugs help reduce cravings and alleviate nicotine withdrawal symptoms. They deliver nicotine in alternative forms, such as chewing gum or patches, for a limited period, thus mitigating withdrawal symptoms and the urge to smoke.

The major products within the category of quit-smoking drugs include drug therapy, electronic cigarettes, nicotine inhalers, nicotine replacement therapies, and nicotine sublingual tablets. Drug therapy involves the use of medications to treat or prevent diseases related to smoking cessation. Medications such as Varenicline (Chantix), Bupropion (Zyban), and others are available through various channels, including drug stores, online pharmacies, and retail pharmacies.

The quit smoking drugs market research report is one of a series of new reports that provides quit smoking drugs market statistics, including quit smoking drugs industry global market size, regional shares, competitors with a quit smoking drugs market share, detailed quit smoking drugs market segments, market trends and opportunities, and any further data you may need to thrive in the quit smoking drugs industry. This quit smoking drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The quit-smoking drugs market consists of sales of AXS-05, cytisincline, nadolol, and liraglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Quit Smoking Drugs Market Characteristics3. Quit Smoking Drugs Market Trends and Strategies4. Quit Smoking Drugs Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
5. Global Quit Smoking Drugs Growth Analysis and Strategic Analysis Framework
5.1. Global Quit Smoking Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis of End Use Industries
5.3. Global Quit Smoking Drugs Market Growth Rate Analysis
5.4. Global Quit Smoking Drugs Historic Market Size and Growth, 2019-2024, Value ($ Billion)
5.5. Global Quit Smoking Drugs Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
5.6. Global Quit Smoking Drugs Total Addressable Market (TAM)
6. Quit Smoking Drugs Market Segmentation
6.1. Global Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drug Therapy
  • E-Cigarettes
  • Nicotine Inhalers
  • Nicotine Replacement Therapies
  • Nicotine Sublingual Tablets
6.2. Global Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Varenicline (Chantix)
  • Bupropion (Zyban)
  • Other Drugs
6.3. Global Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drug Store
  • Online Pharmacies
  • Retail Pharmacies
6.4. Global Quit Smoking Drugs Market, Sub-Segmentation of Drug Therapy, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bupropion (Zyban)
  • Varenicline (Chantix)
6.5. Global Quit Smoking Drugs Market, Sub-Segmentation of E-Cigarettes, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Disposable E-Cigarettes
  • Rechargeable E-Cigarettes
  • Pod Systems
6.6. Global Quit Smoking Drugs Market, Sub-Segmentation of Nicotine Inhalers, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prescription Inhalers
  • Over-the-Counter Inhalers
6.7. Global Quit Smoking Drugs Market, Sub-Segmentation of Nicotine Replacement Therapies (NRT), by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nicotine Patches
  • Nicotine Gum
  • Nicotine Lozenges
6.8. Global Quit Smoking Drugs Market, Sub-Segmentation of Nicotine Sublingual Tablets, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fast-Acting Sublingual Tablets
  • Extended-Release Sublingual Tablets
7. Quit Smoking Drugs Market Regional and Country Analysis
7.1. Global Quit Smoking Drugs Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Quit Smoking Drugs Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Quit Smoking Drugs Market
8.1. Asia-Pacific Quit Smoking Drugs Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Quit Smoking Drugs Market
9.1. China Quit Smoking Drugs Market Overview
9.2. China Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Quit Smoking Drugs Market
10.1. India Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Quit Smoking Drugs Market
11.1. Japan Quit Smoking Drugs Market Overview
11.2. Japan Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Quit Smoking Drugs Market
12.1. Australia Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Quit Smoking Drugs Market
13.1. Indonesia Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Quit Smoking Drugs Market
14.1. South Korea Quit Smoking Drugs Market Overview
14.2. South Korea Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Quit Smoking Drugs Market
15.1. Western Europe Quit Smoking Drugs Market Overview
15.2. Western Europe Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Quit Smoking Drugs Market
16.1. UK Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Quit Smoking Drugs Market
17.1. Germany Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Quit Smoking Drugs Market
18.1. France Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Quit Smoking Drugs Market
19.1. Italy Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Quit Smoking Drugs Market
20.1. Spain Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Quit Smoking Drugs Market
21.1. Eastern Europe Quit Smoking Drugs Market Overview
21.2. Eastern Europe Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Quit Smoking Drugs Market
22.1. Russia Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Quit Smoking Drugs Market
23.1. North America Quit Smoking Drugs Market Overview
23.2. North America Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Quit Smoking Drugs Market
24.1. USA Quit Smoking Drugs Market Overview
24.2. USA Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Quit Smoking Drugs Market
25.1. Canada Quit Smoking Drugs Market Overview
25.2. Canada Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Quit Smoking Drugs Market
26.1. South America Quit Smoking Drugs Market Overview
26.2. South America Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Quit Smoking Drugs Market
27.1. Brazil Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Quit Smoking Drugs Market
28.1. Middle East Quit Smoking Drugs Market Overview
28.2. Middle East Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Quit Smoking Drugs Market
29.1. Africa Quit Smoking Drugs Market Overview
29.2. Africa Quit Smoking Drugs Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Quit Smoking Drugs Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Quit Smoking Drugs Market, Segmentation by Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Quit Smoking Drugs Market Competitive Landscape and Company Profiles
30.1. Quit Smoking Drugs Market Competitive Landscape
30.2. Quit Smoking Drugs Market Company Profiles
30.2.1. 22nd Century Group Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Dr. Reddy's Laboratories Overview, Products and Services, Strategy and Financial Analysis
30.2.4. GSK Plc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
31. Quit Smoking Drugs Market Other Major and Innovative Companies
31.1. NJOY LLC
31.2. Novartis AG
31.3. Perrigo Company Plc
31.4. Pfizer Inc.
31.5. Philip Morris International
31.6. Glenmark Pharmaceuticals Limited
31.7. Zydus Cadila Healthcare Limited
31.8. Rusan Pharma Ltd.
31.9. BioCorRx Inc.
31.10. CV Sciences Inc.
31.11. Ennaid Therapeutics LLC
31.12. Fertin Pharma a/S
31.13. Gilla Inc.
31.14. Hikma Pharmaceuticals PLC
31.15. Innovus Pharmaceuticals Inc.
32. Global Quit Smoking Drugs Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Quit Smoking Drugs Market34. Recent Developments in the Quit Smoking Drugs Market
35. Quit Smoking Drugs Market High Potential Countries, Segments and Strategies
35.1 Quit Smoking Drugs Market in 2029 - Countries Offering Most New Opportunities
35.2 Quit Smoking Drugs Market in 2029 - Segments Offering Most New Opportunities
35.3 Quit Smoking Drugs Market in 2029 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Quit Smoking Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on quit smoking drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for quit smoking drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The quit smoking drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • the market characteristics section of the report defines and explains the market.
  • the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • the forecasts are made after considering the major factors currently impacting the market. These include:
  • the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) by Product: Drug Therapy; E-Cigarettes; Nicotine Inhalers; Nicotine Replacement Therapies; Nicotine Sublingual Tablets
2) by Drug: Varenicline (Chantix); Bupropion (Zyban); Other Drugs
3) by Distribution: Drug Store; Online Pharmacies; Retail Pharmacies

Subsegments:

1) by Drug Therapy: Bupropion (Zyban); Varenicline (Chantix)
2) by E-Cigarettes: Disposable E-Cigarettes; Rechargeable E-Cigarettes; Pod Systems
3) by Nicotine Inhalers: Prescription Inhalers; Over-the-Counter Inhalers
4) by Nicotine Replacement Therapies (NRT): Nicotine Patches; Nicotine Gum; Nicotine Lozenges
5) by Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets; Extended-Release Sublingual Tablets

Key Companies Mentioned: 22nd Century Group; Cipla Limited; Dr. Reddy's Laboratories; GSK Plc.; Johnson & Johnson

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

Some of the major companies featured in this Quit Smoking Drugs market report include:
  • 22nd Century Group
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • GSK Plc.
  • Johnson & Johnson
  • NJOY LLC
  • Novartis AG
  • Perrigo Company Plc
  • Pfizer Inc.
  • Philip Morris International
  • Glenmark Pharmaceuticals Limited
  • Zydus Cadila Healthcare Limited
  • Rusan Pharma Ltd.
  • BioCorRx Inc.
  • CV Sciences Inc.
  • Ennaid Therapeutics LLC
  • Fertin Pharma A/S
  • Gilla Inc.
  • Hikma Pharmaceuticals PLC
  • Innovus Pharmaceuticals Inc.
  • IntelGenx Technologies Corp.

Table Information